Difference between revisions of "Malignant solid neoplasm, ERBB3-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "====Supportive medications" to "====Supportive therapy")
m
Line 12: Line 12:
 
=All lines of therapy=
 
=All lines of therapy=
 
==Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}==
 
==Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:d9f619|Variant=1}}===
 
===Regimen {{#subobject:d9f619|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 23: Line 23:
 
|}
 
|}
 
''Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.''
 
''Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.''
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
 
*Gene: HER3
 
*Gene: HER3
Line 30: Line 31:
 
====Prior treatment criteria====
 
====Prior treatment criteria====
 
* No prior treatment with HER kinase inhibitors
 
* No prior treatment with HER kinase inhibitors
−
 
+
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
 
*[[Neratinib (Nerlynx)]] 240 mg PO once per day
 
*[[Neratinib (Nerlynx)]] 240 mg PO once per day
Line 37: Line 39:
  
 
'''28-day cycles'''
 
'''28-day cycles'''
−
 
+
</div></div>
 
===References===
 
===References===
−
# '''SUMMIT:''' Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. [https://www.nature.com/articles/nature25475 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29420467 PubMed]
+
# '''SUMMIT:''' Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. [https://www.nature.com/articles/nature25475 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29420467 PubMed] NCT01953926
  
 
[[Category:ERBB3 (HER3) regimens]]
 
[[Category:ERBB3 (HER3) regimens]]

Revision as of 17:34, 28 February 2023

Back to Top

1 regimens on this page
1 variants on this page


All lines of therapy

Neratinib monotherapy

Regimen

Study Evidence
Hyman et al. 2018 (SUMMITHER) Non-randomized basket trial, <20 pts in this subgroup

Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.

Biomarker eligibility criteria

  • Gene: HER3
  • Alteration: various substitutions
  • Acceptable methods of measurement: next-generation sequencing assay or RT-PCR, Sanger, pyrosequencing, or mass spectrometry-based sequencing methods

Prior treatment criteria

  • No prior treatment with HER kinase inhibitors

Targeted therapy

Supportive therapy

28-day cycles

References

  1. SUMMIT: Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01953926
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_solid_neoplasm,_ERBB3-mutated&oldid=66666"